SAREPTA THERAPEUTICS, INC. Debt Instrument, Fair Value Disclosure
SAREPTA THERAPEUTICS, INC. (SRPT) had Debt Instrument, Fair Value Disclosure of $910.25 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2026-08-05
- 2026-06-30: Debt Instrument, Fair Value Disclosure $910.25M.
- 2026-03-31: Debt Instrument, Fair Value Disclosure $878.13M.
- 2025-12-31: Debt Instrument, Fair Value Disclosure $864.87M.
- 2025-09-30: Debt Instrument, Fair Value Disclosure $879.57M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $910.25M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $878.13M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $864.87M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $879.57M 10-Q · filed 2025-11-06 |
| 2024-12-31 | $1.25B 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.48B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.69B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.52B 10-Q · filed 2024-05-01 |
| 2023-12-31 | $1.32B 10-K · filed 2025-02-28 |
| 2023-09-30 | $1.48B 10-Q · filed 2023-11-01 |
| 2023-06-30 | $1.45B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $1.59B 10-Q · filed 2023-05-02 |
| 2022-12-31 | $2.07B 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.90B 10-Q · filed 2022-11-02 |
| 2021-12-31 | $1.42B 10-K · filed 2023-02-28 |
| 2020-12-31 | $1.94B 10-K · filed 2022-03-01 |
| 2019-12-31 | $1.39B 10-K · filed 2021-03-01 |
| 2018-12-31 | $952.68M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |